{"product_id":"ara290-10mg-vial","title":"ARA290 10mg vial","description":"\u003cp class=\"\" data-end=\"996\" data-start=\"344\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"996\" data-start=\"344\"\u003e\u003cstrong data-end=\"355\" data-start=\"344\"\u003eARA 290\u003c\/strong\u003e, also known as \u003cstrong data-end=\"385\" data-start=\"371\"\u003eCibinetide\u003c\/strong\u003e, is an 11-amino acid synthetic peptide derived from the B-helix of erythropoietin (EPO). Engineered to selectively activate the \u003cstrong data-end=\"546\" data-start=\"514\"\u003eInnate Repair Receptor (IRR)\u003c\/strong\u003e—a heteromeric complex of the EPO receptor (EPOR) and β-common receptor (CD131)—ARA 290 aims to harness EPO's tissue-protective and anti-inflammatory properties without stimulating erythropoiesis. This selective mechanism positions ARA 290 as a promising therapeutic candidate for conditions characterized by inflammation and tissue injury, such as \u003cstrong data-end=\"927\" data-start=\"895\"\u003esmall fiber neuropathy (SFN)\u003c\/strong\u003e, \u003cstrong data-end=\"952\" data-start=\"929\"\u003ediabetic neuropathy\u003c\/strong\u003e, and \u003cstrong data-end=\"995\" data-start=\"958\"\u003esarcoidosis-associated neuropathy\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"1001\" data-start=\"998\"\u003e\n\u003ch2 class=\"\" data-end=\"1032\" data-start=\"1003\"\u003e\u003cstrong data-end=\"1032\" data-start=\"1006\"\u003e2. Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"1300\" data-start=\"1034\"\u003eARA 290's therapeutic effects are mediated through its selective binding to the IRR, which is upregulated in response to tissue injury and inflammation. Activation of the IRR initiates a cascade of cytoprotective and anti-inflammatory signaling pathways, leading to:\u003c\/p\u003e\n\u003cul data-end=\"1815\" data-start=\"1302\"\u003e\n\u003cli class=\"\" data-end=\"1416\" data-start=\"1302\"\u003e\n\u003cp class=\"\" data-end=\"1416\" data-start=\"1304\"\u003e\u003cstrong data-end=\"1349\" data-start=\"1304\"\u003eSuppression of pro-inflammatory cytokines\u003c\/strong\u003e: Reducing levels of TNF-α, IL-6, and other inflammatory mediators.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1550\" data-start=\"1417\"\u003e\n\u003cp class=\"\" data-end=\"1550\" data-start=\"1419\"\u003e\u003cstrong data-end=\"1459\" data-start=\"1419\"\u003eInhibition of the NLRP3 inflammasome\u003c\/strong\u003e: Attenuating inflammasome activation, which plays a role in various inflammatory diseases.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1656\" data-start=\"1551\"\u003e\n\u003cp class=\"\" data-end=\"1656\" data-start=\"1553\"\u003e\u003cstrong data-end=\"1583\" data-start=\"1553\"\u003ePromotion of tissue repair\u003c\/strong\u003e: Enhancing angiogenesis, neurogenesis, and cellular survival mechanisms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1815\" data-start=\"1657\"\u003e\n\u003cp class=\"\" data-end=\"1815\" data-start=\"1659\"\u003e\u003cstrong data-end=\"1697\" data-start=\"1659\"\u003eRegeneration of small nerve fibers\u003c\/strong\u003e: Stimulating the regrowth of damaged unmyelinated and thinly myelinated nerve fibers, crucial in conditions like SFN.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"1979\" data-start=\"1817\"\u003eImportantly, ARA 290 does not engage the homodimeric EPOR responsible for erythropoiesis, thereby avoiding hematopoietic side effects associated with EPO therapy.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"1984\" data-start=\"1981\"\u003e\n\u003ch2 class=\"\" data-end=\"2013\" data-start=\"1986\"\u003e\u003cstrong data-end=\"2013\" data-start=\"1989\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 class=\"\" data-end=\"2072\" data-start=\"2015\"\u003e\u003cstrong data-end=\"2072\" data-start=\"2019\"\u003e3.1. Small Fiber Neuropathy (SFN) and Sarcoidosis\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"2244\" data-start=\"2074\"\u003eIn a randomized, placebo-controlled trial involving patients with sarcoidosis-associated SFN, subcutaneous administration of ARA 290 (4 mg daily for 28 days) resulted in:\u003c\/p\u003e\n\u003cul data-end=\"2599\" data-start=\"2246\"\u003e\n\u003cli class=\"\" data-end=\"2393\" data-start=\"2246\"\u003e\n\u003cp class=\"\" data-end=\"2393\" data-start=\"2248\"\u003e\u003cstrong data-end=\"2299\" data-start=\"2248\"\u003eSignificant improvement in neuropathic symptoms\u003c\/strong\u003e: Measured by the Small Fiber Neuropathy Screening List (SFNSL) and PainDetect questionnaires.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2518\" data-start=\"2394\"\u003e\n\u003cp class=\"\" data-end=\"2518\" data-start=\"2396\"\u003e\u003cstrong data-end=\"2444\" data-start=\"2396\"\u003eIncreased corneal nerve fiber density (CNFD)\u003c\/strong\u003e: Assessed via corneal confocal microscopy, indicating nerve regeneration.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2599\" data-start=\"2519\"\u003e\n\u003cp class=\"\" data-end=\"2599\" data-start=\"2521\"\u003e\u003cstrong data-end=\"2549\" data-start=\"2521\"\u003eEnhanced quality of life\u003c\/strong\u003e: Improvements noted in the RAND-36 health survey.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"2738\" data-start=\"2601\"\u003eThese benefits persisted beyond the treatment period, suggesting sustained neuroprotective effects.\u003c\/p\u003e\n\u003ch3 class=\"\" data-end=\"2772\" data-start=\"2740\"\u003e\u003cstrong data-end=\"2772\" data-start=\"2744\"\u003e3.2. Diabetic Neuropathy\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"2896\" data-start=\"2774\"\u003eA Phase 2 clinical trial evaluated ARA 290 in patients with type 2 diabetes and painful neuropathy. Key findings included:\u003c\/p\u003e\n\u003cul data-end=\"3309\" data-start=\"2898\"\u003e\n\u003cli class=\"\" data-end=\"3003\" data-start=\"2898\"\u003e\n\u003cp class=\"\" data-end=\"3003\" data-start=\"2900\"\u003e\u003cstrong data-end=\"2929\" data-start=\"2900\"\u003eImproved glycemic control\u003c\/strong\u003e: Reduction in HbA1c levels maintained during a 56-day observation period.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3104\" data-start=\"3004\"\u003e\n\u003cp class=\"\" data-end=\"3104\" data-start=\"3006\"\u003e\u003cstrong data-end=\"3035\" data-start=\"3006\"\u003eLipid profile enhancement\u003c\/strong\u003e: Favorable changes in cholesterol\/HDL ratio and triglyceride levels.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3188\" data-start=\"3105\"\u003e\n\u003cp class=\"\" data-end=\"3188\" data-start=\"3107\"\u003e\u003cstrong data-end=\"3142\" data-start=\"3107\"\u003eAlleviation of neuropathic pain\u003c\/strong\u003e: Significant reductions in PainDetect scores.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3309\" data-start=\"3189\"\u003e\n\u003cp class=\"\" data-end=\"3309\" data-start=\"3191\"\u003e\u003cstrong data-end=\"3219\" data-start=\"3191\"\u003eNerve fiber regeneration\u003c\/strong\u003e: Increased CNFD in patients with baseline deficits.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"3347\" data-start=\"3311\"\u003e\u003cstrong data-end=\"3347\" data-start=\"3315\"\u003e3.3. Other Therapeutic Areas\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"3410\" data-start=\"3349\"\u003ePreclinical studies have demonstrated ARA 290's potential in:\u003c\/p\u003e\n\u003cul data-end=\"3861\" data-start=\"3412\"\u003e\n\u003cli class=\"\" data-end=\"3518\" data-start=\"3412\"\u003e\n\u003cp class=\"\" data-end=\"3518\" data-start=\"3414\"\u003e\u003cstrong data-end=\"3451\" data-start=\"3414\"\u003eRenal ischemia\/reperfusion injury\u003c\/strong\u003e: Enhancing glomerular filtration rate and reducing tubular damage.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3620\" data-start=\"3519\"\u003e\n\u003cp class=\"\" data-end=\"3620\" data-start=\"3521\"\u003e\u003cstrong data-end=\"3564\" data-start=\"3521\"\u003eMyocardial infarction and heart failure\u003c\/strong\u003e: Attenuating cardiac remodeling and improving function.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3711\" data-start=\"3621\"\u003e\n\u003cp class=\"\" data-end=\"3711\" data-start=\"3623\"\u003e\u003cstrong data-end=\"3659\" data-start=\"3623\"\u003eBurns and traumatic brain injury\u003c\/strong\u003e: Promoting tissue repair and reducing inflammation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3861\" data-start=\"3712\"\u003e\n\u003cp class=\"\" data-end=\"3861\" data-start=\"3714\"\u003e\u003cstrong data-end=\"3728\" data-start=\"3714\"\u003eDepression\u003c\/strong\u003e: Ameliorating depression-like behaviors in animal models through anti-inflammatory mechanisms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3866\" data-start=\"3863\"\u003e\n\u003ch2 class=\"\" data-end=\"3901\" data-start=\"3868\"\u003e\u003cstrong data-end=\"3901\" data-start=\"3871\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3952\" data-start=\"3903\"\u003eARA 290 has exhibited a favorable safety profile:\u003c\/p\u003e\n\u003cul data-end=\"4265\" data-start=\"3954\"\u003e\n\u003cli class=\"\" data-end=\"4037\" data-start=\"3954\"\u003e\n\u003cp class=\"\" data-end=\"4037\" data-start=\"3956\"\u003e\u003cstrong data-end=\"3977\" data-start=\"3956\"\u003eNon-hematopoietic\u003c\/strong\u003e: No significant changes in hemoglobin or hematocrit levels.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4113\" data-start=\"4038\"\u003e\n\u003cp class=\"\" data-end=\"4113\" data-start=\"4040\"\u003e\u003cstrong data-end=\"4058\" data-start=\"4040\"\u003eWell-tolerated\u003c\/strong\u003e: Absence of serious adverse events in clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4265\" data-start=\"4114\"\u003e\n\u003cp class=\"\" data-end=\"4265\" data-start=\"4116\"\u003e\u003cstrong data-end=\"4135\" data-start=\"4116\"\u003eShort half-life\u003c\/strong\u003e: Approximately 20 minutes, yet elicits prolonged therapeutic effects due to IRR activation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"4270\" data-start=\"4267\"\u003e\n\u003ch2 class=\"\" data-end=\"4298\" data-start=\"4272\"\u003e\u003cstrong data-end=\"4298\" data-start=\"4275\"\u003e5. Pharmacokinetics\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-end=\"4581\" data-start=\"4300\"\u003e\n\u003cli class=\"\" data-end=\"4345\" data-start=\"4300\"\u003e\n\u003cp class=\"\" data-end=\"4345\" data-start=\"4302\"\u003e\u003cstrong data-end=\"4320\" data-start=\"4302\"\u003eAdministration\u003c\/strong\u003e: Subcutaneous injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4453\" data-start=\"4346\"\u003e\n\u003cp class=\"\" data-end=\"4453\" data-start=\"4348\"\u003e\u003cstrong data-end=\"4367\" data-start=\"4348\"\u003eBioavailability\u003c\/strong\u003e: Rapid absorption with peak plasma concentrations (~3 ng\/mL) achieved post-injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4581\" data-start=\"4454\"\u003e\n\u003cp class=\"\" data-end=\"4581\" data-start=\"4456\"\u003e\u003cstrong data-end=\"4478\" data-start=\"4456\"\u003eDuration of action\u003c\/strong\u003e: Despite a short plasma half-life, the downstream effects of IRR activation confer sustained benefits.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"4586\" data-start=\"4583\"\u003e\n\u003ch2 class=\"\" data-end=\"4637\" data-start=\"4588\"\u003e\u003cstrong data-end=\"4637\" data-start=\"4591\"\u003e6. Regulatory Status and Future Directions\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"4872\" data-start=\"4639\"\u003eWhile ARA 290 has shown promise in early-phase clinical trials, it has not yet received regulatory approval for clinical use. Ongoing research aims to further elucidate its therapeutic potential across various indications, including:\u003c\/p\u003e\n\u003cul data-end=\"5189\" data-start=\"4874\"\u003e\n\u003cli class=\"\" data-end=\"4999\" data-start=\"4874\"\u003e\n\u003cp class=\"\" data-end=\"4999\" data-start=\"4876\"\u003e\u003cstrong data-end=\"4909\" data-start=\"4876\"\u003eChronic inflammatory diseases\u003c\/strong\u003e: Exploring efficacy in conditions like multiple sclerosis and inflammatory bowel disease.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5093\" data-start=\"5000\"\u003e\n\u003cp class=\"\" data-end=\"5093\" data-start=\"5002\"\u003e\u003cstrong data-end=\"5026\" data-start=\"5002\"\u003eOphthalmic disorders\u003c\/strong\u003e: Investigating benefits in diabetic retinopathy and macular edema.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5189\" data-start=\"5094\"\u003e\n\u003cp class=\"\" data-end=\"5189\" data-start=\"5096\"\u003e\u003cstrong data-end=\"5123\" data-start=\"5096\"\u003eAutoimmune neuropathies\u003c\/strong\u003e: Assessing effects in conditions such as Guillain-Barré syndrome.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"5336\" data-start=\"5191\"\u003eContinued clinical development and larger-scale trials are necessary to validate these applications and facilitate potential regulatory approval.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"5341\" data-start=\"5338\"\u003e\n\u003ch2 class=\"\" data-end=\"5363\" data-start=\"5343\"\u003e\u003cstrong data-end=\"5363\" data-start=\"5346\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"5823\" data-start=\"5365\"\u003eARA 290 represents a novel class of therapeutic agents that selectively activate tissue-protective pathways without eliciting erythropoietic effects. Its ability to modulate inflammation, promote tissue repair, and regenerate nerve fibers positions it as a promising candidate for treating a range of conditions characterized by inflammation and tissue injury. Further clinical studies will be pivotal in determining its place in future therapeutic regimens.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"5828\" data-start=\"5825\"\u003e\n\u003cp class=\"\" data-end=\"5845\" data-start=\"5830\"\u003e\u003cstrong data-end=\"5845\" data-start=\"5830\"\u003eReferences:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col data-end=\"6770\" data-start=\"5847\"\u003e\n\u003cli class=\"\" data-end=\"6107\" data-start=\"5847\"\u003e\n\u003cp class=\"\" data-end=\"6107\" data-start=\"5850\"\u003eBrines, M., et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. \u003cem data-end=\"6052\" data-start=\"6032\"\u003eMolecular Medicine\u003c\/em\u003e, 20(1), 658–666.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"6350\" data-start=\"6109\"\u003e\n\u003cp class=\"\" data-end=\"6350\" data-start=\"6112\"\u003eHeij, L., et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. \u003cem data-end=\"6293\" data-start=\"6273\"\u003eMolecular Medicine\u003c\/em\u003e, 18(1), 1430–1436.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"6522\" data-start=\"6352\"\u003e\n\u003cp class=\"\" data-end=\"6522\" data-start=\"6355\"\u003eOttens, P., et al. (2013). ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia\/reperfusion injury. \u003cem data-end=\"6508\" data-start=\"6473\"\u003eJournal of Translational Medicine\u003c\/em\u003e, 11(1), 1–10.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"6770\" data-start=\"6524\"\u003e\n\u003cp class=\"\" data-end=\"6770\" data-start=\"6527\"\u003eXu, G., et al. (2022). Nonerythropoietic erythropoietin mimetic peptide ARA290 ameliorates chronic stress-induced depression-like behavior and inflammation in mice. \u003cem data-end=\"6719\" data-start=\"6692\"\u003eFrontiers in Pharmacology\u003c\/em\u003e, 13, 896601.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684859736402,"sku":null,"price":60.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/ara290_10mg.png?v=1770834900","url":"https:\/\/sciencepeptideslab.com\/products\/ara290-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}